Chemotherapy Induced Secondary Spontaneous Pneumothorax in a Female with Endometrial Cancer-A Case Report

Srinivas Naik a#, Shazia Mohammad b#, Sourya Acharya a†, Neema Acharya b† and Anuj Varma a¥

a Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, Maharashtra, India.
b Department of Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, Maharashtra, India.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i62B35168

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/79447

Received 20 October 2021
Accepted 27 December 2021
Published 29 December 2021

ABSTRACT

Endometrial cancer is one of the leading causes of death in post-menopausal women. It has significant impact on mortality and morbidity of women in the post-menopausal age group often requiring Hysterectomy along with Chemotherapy. Chemotherapy can be used to treat endometrial cancer with hematogenous metastases. Chemotherapy induced secondary pneumothorax is a rare complication. We present a case of a 68-year-old female patient with endometrial cancer who had pulmonary metastasis and was subjected to carboplatin, paclitaxel-based chemotherapy. During the fourth cycle she developed tension pneumothorax. This case highlights the importance of knowledge of life-threatening complications of chemotherapy regimens, so that the treating of physician/oncologists are ready to tackle these anticipated conditions.
Keywords: Cancer; cycle; chemotherapy; endometrial.

1. INTRODUCTION

The most prevalent gynaecological malignancy in women is endometrial cancer. Endometrial cancer accounts for over 5% of diagnosed cancers and about 2% of cancer related mortality in women worldwide [1]. In developed countries, it is the 4th most common malignant tumour in females. Genetic variables, anthropometric characteristics, lifestyle factors (e.g., cigarette smoking, alcoholism, physical inactivity, and regular diet), and clinical disorders (e.g., diabetes, polycystic ovary) are all linked to endometrial cancer risk, according to current research. Furthermore, numerous reproductive variables that enhance continuous oestrogen stimulation, including as parity age at menarche, oral contraceptive use [2], and breastfeeding, can raise the risk of endometrial cancer.

Individuals with stage IIIB or stage IIIC illness of any histology, as well as patients with stages IA (with myometrial invasion), IB, II, or IIIA serous or clear cell carcinoma, should consider adjuvant treatment, according to current NCCN guidelines.

Pneumothorax is the presence of air in the pleural space. The most common mechanism involved in pneumothorax are: 1) communication between alveolar spaces and pleura; 2) direct or indirect communication between the atmosphere and the pleural space; or 3) presence of gas-producing organisms in the pleural space [3,4]. Secondary spontaneous pneumothorax may be caused by a variety of conditions like chronic obstructive pulmonary disease, malignancies, vasculitis, collagen vascular disorders, trauma [5,6,7,8].

One main cause of spontaneous pneumothorax is when it occurs secondarily to malignancy, either original lung malignancy or metastasis to pulmonary tissue. Metastatic lung sarcoma [9,10] is the most common cancer that causes secondary spontaneous pneumothoraces; however, primary lung cancer [11], renal cell carcinoma [12], breast malignancy [13], thyroid neoplasms [14], germ cell tumour , and lymphomas in the mediastinum have also been implicated in development of pneumothorax.

2. CASE REPORT

A 68-year-old woman (para 2 living 2) presented to out patient department, with complaints of postmenopausal bleeding on & off since past 4 months; bleeding had increased from past 1 week which warranted her visit to hospital. After an initial gynaecological examination, and sonographic evaluation which suggested Endometrial thickness of 8 mm; office Biopsy was performed. Histopathology was suggestive of Poorly Differentiated Endometriod carcinoma Grade III. We proceeded with staging laparotomy to stage the cancer and proceeded with Radical hysterectomy (uterus, cervix, bilateral fallopian tubes & bilateral ovaries was removed) with bilateral pelvic lymph nodes dissection (BPLND) along with paraaortic lymph nodes dissection. On Microscopic examination, Tumour was composed predominantly of sheets of cells. Tumour invaded more than half thickness of myometrium & serosa was free of tumour. Lymphovascular emboli were seen; though perineural space invasion was absent. Tumour invaded less than half of cervical stromal thickness. Fallopian tubes & ovaries were free of tumour. Bilateral pelvic lymph node metastasis was present. Paraaortic lymph nodes were free of metastasis. Patient was labelled as FIGO Stage III C1. On immunohistochemistry, Tumour cells showed immunoreactivity for ER & PR (80% Staining) and MLH-1 & PMS-2 showed Loss of nuclear expression; MSH-2, MSH-6, PMS-2 showed intact nuclear expression. Her 2 Neu status as negative. Post-operative chemotherapy with Carboplatin (AUC 5) & Paclitaxel (175 mg/m²) was instituted and without any complications, full remission was achieved after the first three cycles of treatment. She had loss of follow up due to COVID-19 pandemic for 5 months following that. After 5 months, when she visited our hospital, unfortunately, a single metastatic nodule to the lungs, along with multiple nodules on both sides developed when she came for fourth cycle of chemotherapy. After the fourth cycle of chemotherapy was administered; She suddenly developed chest pain on right side which was severe, sharp & was radiating to ipsilateral shoulder & arm. It was also associated shortness of breath & cough. On examination patient was tachypnic with a respiratory rate of 35 cycles/min, heart rate was 152 beats per minute, BP was 90/60 mm hg, SpO2 while breathing ambient air was 78%. Respiratory system examination revealed diminished chest movements on left hemithorax, Trachea was grossly shifted to right side, hyper resonant note was present on left hemithorax in
percussion, air entry was absent on left hemithorax.

Patient was immediately given high flow oxygen 12 litres per minute through nasal cannula and an urgent x ray of chest (Image 1.) revealed massive pneumothorax on left side with gross mediastinal shift. Immediate intercostal chest tube drainage was performed and the patient's condition stabilised.

3. DISCUSSION

The aetiology of a spontaneous pneumothorax determines whether it is primary or secondary. Rapid shrinkage of a pulmonary space-occupying tumor sometimes causes rare but life-threatening spontaneous pneumothoraces [15].

The mechanism that causes primary spontaneous pneumothoraces is unknown. Secondary spontaneous pneumothoraces, on the other hand, are caused by a number of disorders that impact the airways and parenchyma. One reason for the development of spontaneous pneumothoraces is secondary to a malignancy, either original lung malignancy or metastasis to pleural or pulmonary tissue. Secondary pneumothorax is most commonly seen as a result of metastatic lung sarcoma; however, secondary spontaneous pneumothoraces have also been reported in patients with pulmonary tumours, thyroid malignancy, sex cord tumour, breast neoplasms, renal cell carcinoma, and lymphomas.

The possible mechanisms may be tumours directly damaging broncho-alveolar tissue, capillary endothelium, and the pleural tissue [16]. A second idea is that various treatment techniques, such as chemotherapy or molecular targeted therapy, produce fast shrinking of space-occupying tumours [12]. Third, molecularly targeted therapeutics, particularly gefitinib, inhibit alveolar capillary development and injure normal tissue [17]. A chemosensitive lung metastatic cancer may have decreased rapidly after successful chemotherapy in the example documented here, resulting in a spontaneous pneumothorax. Another latest alternative to chemotherapy could be immune checkpoint inhibitors. Different immune checkpoint pathways that have immunosuppressive properties can be activated by cancer cells. Monoclonal antibodies
that target immunological checkpoints have made a significant contribution to cancer treatment. PD-1/PD-L1 and CTLA-4 inhibitors are among the immune checkpoint inhibitors that have shown promising therapeutic results; some have been licenced for specific cancer therapies, while others are still in clinical studies. According to recent studies, immune checkpoint inhibitor therapy helps patients with a variety of cancers.

In the example documented here, a metastatic cancer of the lung which is sensitive to chemotherapy reduced rapidly in size due to successful chemotherapy resulting in spontaneous pneumothorax. The consequences of a delayed pneumothorax diagnosis are substantial and life-threatening. This could be the first incidence of a spontaneous pneumothorax occurring after receiving paclitaxel and carboplatin for metastatic endometrial cancer treatment.

4. CONCLUSION

We should be on the alert for any pulmonary issues following chemotherapy & fast shrinking of pulmonary tumours. Spontaneous pneumothorax is an uncommon but potentially fatal situation that can strike at any time.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

14. Kryger-Baggesen N. Spontaneous pneumothorax following regression of


